Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2024 Filed Apr 3, 2024 18:41 UTC |
Stahler Rachel AChief Information Officer
|
GrantCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000048 · wk-form4_1712184102.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,150 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 7,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · derivative · entry 6 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,590 Underlying: Common Stock · 7,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionRestricted Stock Units · Derivative | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · derivative · entry 5 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,937 Underlying: Common Stock · 3,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 2,328 | $18.80 | $43,766.40 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 4 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,802 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 7,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Tax withholdingCommon Stock | 1,712 | $18.80 | $32,185.60 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,336 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:42 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
Exercise / conversionCommon Stock | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000051 · wk-form4_1712184144.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 4,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · derivative · entry 6 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,212 Underlying: Common Stock · 4,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 2,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · derivative · entry 5 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,863 Underlying: Common Stock · 2,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,578 | $18.80 | $29,666.40 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · nonDerivative · entry 4 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,019 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 4,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · nonDerivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 981 | $18.80 | $18,442.80 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,991 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 2,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000047 · wk-form4_1712184087.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 38,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · derivative · entry 6 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,948 Underlying: Common Stock · 38,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · derivative · entry 5 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,472 Underlying: Common Stock · 21,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 21,553 | $18.80 | $405,196.40 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 4 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,343 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 38,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 3 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 11,874 | $18.80 | $223,231.20 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,923 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Ali KevinDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 21,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000046 · wk-form4_1712184071.xml · nonDerivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · derivative · entry 6 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,464 Underlying: Common Stock · 6,731 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F3 · derivative.exercise_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. F3 · derivative.expiration_date: On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,579 Underlying: Common Stock · 3,578 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. F2 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 2,306 | $18.80 | $43,352.80 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · nonDerivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,594 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 6,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · nonDerivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 1,226 | $18.80 | $23,048.80 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,169 Read SEC document |
| March 31, 2024 Filed Apr 3, 2024 22:41 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 3,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000045 · wk-form4_1712184047.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:27 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 119,825 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000028 · wk-form4_1712089623.xml · derivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,825 Underlying: Common Stock · 119,825 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:27 UTC |
Fiedler SusanneChief Commercial Officer
|
GrantRestricted Stock Units · Derivative | 29,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000028 · wk-form4_1712089623.xml · derivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,255 Underlying: Common Stock · 29,255 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantStock Option (right to buy) · Derivative | 95,315 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000022 · wk-form4_1712089307.xml · derivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,315 Underlying: Common Stock · 95,315 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantRestricted Stock Units · Derivative | 23,271 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000022 · wk-form4_1712089307.xml · derivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,271 Underlying: Common Stock · 23,271 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC |
DiMarco KathrynCorporate Controller
|
GrantRestricted Stock Units · Derivative | 31,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000021 · wk-form4_1712089273.xml · derivative · entry 1 DiMarco Kathryn · CIK 0001861045 · Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,914 Underlying: Common Stock · 31,914 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:12 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 185,185 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000018 · wk-form4_1712088709.xml · derivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,185 Underlying: Common Stock · 185,185 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:12 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 45,212 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000018 · wk-form4_1712088709.xml · derivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,212 Underlying: Common Stock · 45,212 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC |
Stahler Rachel AChief Information Officer
|
GrantStock Option (right to buy) · Derivative | 100,762 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000020 · wk-form4_1712089246.xml · derivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,762 Underlying: Common Stock · 100,762 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 16:21 UTC |
Stahler Rachel AChief Information Officer
|
GrantRestricted Stock Units · Derivative | 24,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000020 · wk-form4_1712089246.xml · derivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,601 Underlying: Common Stock · 24,601 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:29 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 599,128 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000033 · wk-form4_1712089757.xml · derivative · entry 2 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 599,128 Underlying: Common Stock · 599,128 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:29 UTC |
Ali KevinDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 146,276 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000033 · wk-form4_1712089757.xml · derivative · entry 1 Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,276 Underlying: Common Stock · 146,276 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:28 UTC |
Falcione AaronChief Human Resources Officer
|
GrantStock Option (right to buy) · Derivative | 103,485 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000030 · wk-form4_1712089689.xml · derivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,485 Underlying: Common Stock · 103,485 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:28 UTC |
Falcione AaronChief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 25,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000030 · wk-form4_1712089689.xml · derivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,265 Underlying: Common Stock · 25,265 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:24 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantStock Option (right to buy) · Derivative | 119,825 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000026 · wk-form4_1712089486.xml · derivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,825 Underlying: Common Stock · 119,825 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:24 UTC |
Morrissey Joseph T. Jr.Head of Manufacturing
|
GrantRestricted Stock Units · Derivative | 29,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000026 · wk-form4_1712089486.xml · derivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,255 Underlying: Common Stock · 29,255 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:23 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantStock Option (right to buy) · Derivative | 70,806 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000024 · wk-form4_1712089389.xml · derivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,806 Underlying: Common Stock · 70,806 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:23 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantRestricted Stock Units · Derivative | 17,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000024 · wk-form4_1712089389.xml · derivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,287 Underlying: Common Stock · 17,287 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 16, 2024 10:23 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
GrantStock Option (right to buy) · Derivative | 108,932 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001821825-24-000053 · wk-form4_1713263007.xml · derivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,932 Underlying: Common Stock · 108,932 shares Expires 2027-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2024 Filed Apr 16, 2024 10:23 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
GrantRestricted Stock Units · Derivative | 26,595 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000053 · wk-form4_1713263007.xml · derivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,595 Underlying: Common Stock · 26,595 shares Expires 2027-03-29 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 19,827 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,827 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
Fiedler SusanneChief Commercial Officer
|
Tax withholdingCommon Stock | 6,316 | $18.04 | $113,940.64 |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · nonDerivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,702 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:22 UTC |
Fiedler SusanneChief Commercial Officer
|
Exercise / conversionCommon Stock | 19,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000006 · wk-form4_1709328157.xml · nonDerivative · entry 1 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 4,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,957 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.exercise_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. F2 · derivative.expiration_date: As previously reported, these Restricted Stock Units vested on December 31, 2023, and shares of Organon & Co. common stock were distributed to the Reporting Person on February 28, 2024. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 1,607 | $18.04 | $28,990.28 |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,531 Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 16:24 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 4,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001821825-24-000013 · wk-form4_1709328287.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.